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Magnetic nanoparticles (NPs) MnFe2O4 and Fe3O4 were stabilised by depositing an Al(OH)3 layer via a
hydrolysis process. The particles displayed excellent colloidal stability in water and a high afﬁnity to
[18F]-ﬂuoride and bisphosphonate groups. A high radiolabeling efﬁciency, 97% for 18F-ﬂuoride and 100%
for 64Cu-bisphosphonate conjugate, was achieved by simply incubating NPs with radioactivity solution at
room temperature for 5 min. The properties of particles were strongly dependant on the thickness and
hardness of the Al(OH)3 layer which could in turn be controlled by the hydrolysis method. The appli-
cation of these Al(OH)3 coated magnetic NPs in molecular imaging has been further explored. The results
demonstrated that these NPs are potential candidates as dual modal probes for MR and PET. In vivo PET
imaging showed a slow release of 18F from NPs, but no sign of efﬂux of 64Cu.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Superparamagnetic nanoparticles (NPs) have been intensively
investigated due to their potential applications in biosensors [1e3],
targeted drug delivery [4e7], MRI [8,9] and localised hyperthermia
induction [10,11]. An obstacle to application of these NPs is that
they tend to aggregate and form larger secondary particles, in order
to minimise their surface energy. Moreover, magnetic NPs are most
often synthesised in organic solvents and coated with an organicision of Imaging Sciences and
homas’ Hospital, London SE1
42.
ision of Imaging Sciences and
homas’ Hospital, London SE1
een), philip.blower@kcl.ac.uk
r Ltd. This is an open access articlelayer of oleylamine or oleic acid rendering them soluble only in
non-polar solvents. On the other hand, medical or bio-applications
require colloidal stability and dispersibility in water and biological
environments. Many methods have been developed to obtain sta-
ble colloids of magnetic NPs, reviewed by Laurent et al. [12].
Amongst them, coating with polyethyleneglycol (PEG) [8] or
Dextran [13] has been widely used, as these hydrophilic and
biocompatible materials not only provide a steric barrier against
aggregation, but also make them hardly recognised by the
macrophage-monocytic system [14]. To avoid desorption of the
polymeric coating by heating or dilution, one or more functional
groups, such as carbonate or phosphonate, are necessary to bind
with the NPs. Such polymers, however, involve a complicated
multi-step synthesis approach [8,15]. Therefore the use of an
inorganic shell material that introduces stability, functionality and
water-solubility is desirable.
Herein, we report a simple approach to stabilise magnetic NPs
by coating them with an Al(OH)3 layer. The aluminium hydroxideunder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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[16] and bisphosphonate groups [17], which allow easy radio-
labelling and functionalisation, and its biocompatibility as shown
by its application in vaccine adjuvants [18].
2. Experimental section
2.1. Materials and general characterisation
All chemicals were used as purchased without further puriﬁcation. Deionised
water was obtained from an ELGA PureLab Option Q system. Bisphosphonate pol-
yethyleneglycol (BP-PEG) polymers were synthesised in house according to pub-
lishedmethods [8]. X-Ray powder diffraction (XRD)measurements were recorded at
room temperature on a PANalytical X’Pert PRO diffractometer using Cu-Ka1 radiation
(l ¼ 1.540598 Å) at 40 kV, 40 mA, a scan speed of 0.02/s and a step size of 0.026 in
2q, at Nottingham University. X-Ray photoelectron spectra were recorded using a
Thermo Fisher ESCALAB 250 X-ray Photoelectron Spectrometer with a hemispher-
ical sector energy analyser at Aston University. Monochromatic Al Ka X-ray source
was used at excitation energy of 15 kV and an emission current of 6 mA. The
analyser pass energy of 20 eV with step size of 0.1 eV was used throughout the
experiment. Transmission electronmicroscope (TEM) imageswere taken on a Tecnai
FEI T20 at Centre for Ultrastructural Imaging, King’s College London. Attenuated
total reﬂectance infrared (ATR-IR or IR) spectra were recorded on a Perkin Elmer
spectrum 100. Dynamic light scattering (DLS) experiments were carried out on
Zetasizer Nano ZS from Malvern Instruments with a measure angle 175 and a
632.8 nm laser. Zeta potential for all samples was measured in neutral aqueous
solution with a pH value z7.
2.2. Synthesis
2.2.1. Synthesis of MnFe2O4 and Fe3O4
Magnetic NPs were obtained via amethod reported previously [19,20]. Typically,
6 mmol 1,2-hexadecanediol was added to a 100 ml ﬂask containing 20 ml phenyl
ether, 5 ml oleylamine and 5 ml oleic acid at 120 C, and the resultant solution was
kept at this temperature under vacuum for over 30 min to remove water in the
solvent. To this light yellow solution, 1 mmol Mn(acac)2 and 2 mmol Fe(acac)3 (or
2 mmol Fe(acac)3 for Fe3O4), was added under N2, and then temperature was
increased to 270 C at a rate of 10 C/min with magnetic stirring. After 30 min, the
ﬂask was cooled to room temperature by removal from the hotplate. To precipitate
out the NPs, 40 ml ethanol was added. The particles were collected by centrifugation
(Jouan CR312, at a speed of 3000 rpm for 30 min) and washed with ethanol/hexane
twice.
2.2.2. Synthesis of MnFe2O4@Al(OH)3 (1)
MnFe2O4 (80 mg, 0.33 mmol) was dissolved in 30 ml diethyl ether by sonication
for 20 min to form a dark brown solution, and then 10 ml of a diethyl ether solution
containing AlCl3 (144 mg, 1 mmol) was added dropwise. The mixture was sonicated
for 2 min before the addition of 500 ml water (27.8 mmol). The subsequent addition
of 10 ml acetone led to a brown suspension. The product was collected by centri-
fugation and then dried in a stream of N2 to remove ether and acetone, and re-
dispersed in water.
2.2.3. Synthesis of Fe3O4@Al(OH)3 samples (2e4)
In the case of Fe3O4@Al(OH)3 (with a precursor molar ratio of Fe3O4 to AlCl3 of
1:3) (4), a faster uncontrolled hydrolysis method was used. Fe3O4 (82 mg,
0.33mmol) was dissolved in 30ml diethyl ether after sonication for 20min to form a
dark brown solution, and then 10ml diethyl ether solution containing AlCl3 (144mg,
1 mmol) was added dropwise. The mixture was sonicated for 2 min before the
addition of 10 ml acetone leading to a brown suspension. The product was collected
by centrifugation and then dried with a stream of N2 to remove ether and acetone,
and re-dispersed inwater. Corresponding amounts of AlCl3 were usedwith the same
volume of Et2O to obtain Fe3O4@Al(OH)3 (1:1) (2) and Fe3O4@Al(OH)3 (1:2) (3)
samples with various coreeshell ratios.
2.2.4. Filtration of MFe2O4@Al(OH)3 (M ¼ Mn or Fe)
The Al(OH)3@MFe2O4 solution prepared as described in Section 2.2.2 (200 ml)
was diluted with water (1 ml) to form a transparent brown solution, and then
transferred to a 1 ml centrifuge tube with a ﬁlter inside (NanoSep, cut-off-molecular
size, 30 K). Brown NPs were obtained on the ﬁlter by centrifugation at 5000 rpm for
20 min.
2.2.5. Preparation of Fe3O4@Al(OH)3-BP-PEG(5K)
Bisphosphonate polyethyleneglycol (prepared as described elsewhere [8])
(5 mg) was added to the aqueous solution of Fe3O4@Al(OH)3 (5 ml, ca. 4 mg/ml),
followed by a sonication treatment for 10 min.
2.3. Radiolabelling with 18F and radiochemical stability in water
18F labelling of MFe2O4@Al(OH)3 (M¼Mn, or Fe,1e4) was measured in triplicate
at different concentrations. Typically, 50 ml aqueous [18F]sodium ﬂuoride solutioncontaining ca. 5 MBq radioactivity was added to a 450 ml solution of varying con-
centrations of MnFe2O4@Al(OH)3 in NanoSep with a cutoff size of 30k. After 10 min
incubation with continuous shaking at room temperature, labelled NPs were sepa-
rated by centrifugation at 5000 rpm (Eppendorf centrifuge 5424) for 20 min. The
radioactivity of the supernatant and particles (on the ﬁlter) was measured sepa-
rately using a gamma counter. The labelling efﬁciency was given by the following
Equation (1):
Labelling efficiency ð%Þ ¼ Activity of NPs
Activity of NPsþ Activity of supernatant 100% (1)
Triplicate samples of 18F labelled NPs were separated as described above. The
NPs retained on the ﬁlter were re-suspended in deionised water in the inner
NanoSep tube and then centrifuged at 5000 rpm for 20 min. This step was repeated
three times. The percent binding retained after each washing step was calculated
using equation (1). The correction for cumulative loss of label for the second and
third washing steps was performed as exempliﬁed by the following equation (2):
Cumulative Binding ¼ Activity % in NPs Activity % in NPs prewash (2)
2.4. Radiochemical stability of 18F-labelled 1, 2, 3, 4 in serum
Triplicate samples of labelled NPs were prepared on a NanoSep membrane as
described above. The NPs retained in the ﬁltrate were re-suspended in 25% serum in
water (v/v), incubated at 37 C for a period of up to 6 h, and then centrifuged at
10,000 rpm (Eppendorf centrifuge 5424) for 30 min. The cumulative binding was
calculated using equation (2) as described previously.
2.5. Adsorption of non-radioactive 19F
5 mg NP 1 were dissolved in 5 ml freshly prepared NaF solution with concen-
trations of 0.01 mmol/L, 0.1 mmol/L, 1 mmol/L and 10 mmol/L. The suspensions of
NPs were sonicated with the laboratory sonicator bath for 1 h, and then left over-
night. The samples were centrifuged for 30 min at 3000 rpm (Jouan CR312) and 4 ml
of supernatant was then withdrawn from each sample. The concentrations of
ﬂuoride anions in supernatant and corresponding particle-free NaF solution were
measured with an Orion Star 214 bench-top meter with a ﬂuoride combination
electrode (from Fisher Scientiﬁc). Duplicate samples were prepared for each con-
centration. Adsorption percentage was obtained by dividing the concentration dif-
ference between the supernatant and the initial particle-free solution by the initial
concentration.
2.6. [18F]-ﬂuoride radiolabelling of washed Fe3O4@Al(OH)3 samples
500 ml of 1.34mg/ml suspension of 2 inwater (or 2 mg/ml 3NPs, or 2.35mg/ml 4
NPs) was placed in a NanoSep tubewith omegamembrane (molecular weight cutoff,
30 kDa). The tubes were centrifuged at 5000 rpm (Eppendorf centrifuge 5424) for
20 min, and then these NPs were re-dissolved in 450 ml water. 50 ml [18F]sodium
ﬂuoride (ca. 5 MBq) was added to these NPs solutions in the NanoSep tubes. After
10 min incubation by continuous shaking at room temperature, the tubes were
centrifuged at 5000 rpm for 20 min. As described before, the activities in the ﬁltrate
and remaining on NPs (on the ﬁlter) were separately measured with a gamma
counter, to produce a labelling efﬁciency for the 1st washed Fe3O4@Al(OH)3 samples.
To measure the labelling efﬁciency for 2nd washed NPs, the washing stepwas repeat
twice before incubation with 18F-ﬂuoride radioactivity.
2.7. Radiolabelling of 1 with 64Cu
1 mg bis(dithiocarbamate) bisphosphonate (DTCBP) [15] was dissolved in
100 mM Na2CO3 buffer (pH 9). 200 ml of the above solution was added to 200 ml
64CuCl2 radioactivity (ca. 20 MBq) solution that was buffered to pH 5 with sodium
acetate. It is essential to maintain the solution at neutral pH, since Al(OH)3 is not
stable either in acidic or in basic solution. After 5 min, 200 ml 0.5 mg/ml
MnFe2O4@Al(OH)3 solution containing 0.2 mg/ml PEG-5K was added and the
mixture was incubated at room temperature for another 5 min. The radiolabelled
NPs were isolated by ﬁlter centrifugation at speed of 5000 rpm for 15 min, using a
Nanosep with a cutoff size of 30 K. There was no radioactivity observed in the
ﬁltrate, and all radioactivity remained on NPs in the ﬁlter. The 64Cu radiolabelled NPs
were re-dissolved in 100 ml saline for injection.
2.8. T1, T2 and T2* relaxivity measurement
MR imaging of all particles was performed with a standard extremity ﬂex coil on
a clinical 3T Philips Achieva MRI scanner (Philips Healthcare, Best, The Netherlands).
T1 mapping was obtained by using a 2D sequence that employed two non-selective
inversion pulses with inversion times ranging from 20 to 2000ms, followed by eight
segmented readouts for eight individual images [21]. The two imaging trains
resulted in a set of 16 images per slice with increasing inversion times
(FOV ¼ 200*200 mm, matrix ¼ 200*179 mm, in-plane resolution ¼ 1*1.12 mm,
measured slice thickness ¼ 3 mm, slices ¼ 16, TR/TE ¼ 3.2/1.6 ms, FA ¼ 10). T2 was
Fig. 1. (a) XRD patterns of MnFe2O4 (black line) and MnFe2O4@Al(OH)3 (1) NPs (blue line). The red lines show the reference XRD pattern calculated from the published crystal-
lographic data of Fe3O4 [24]; $ represents the peak of Al(OH)3 (nordstrandite phase) [22]; (b) Photographs of MnFe2O4 (left) and 1 (right) NPs in a two-phase mixture of hexane
(upper layer) and water (lower layer); (c) TEM images of MnFe2O4 NPs isolated from hexane; and (d) TEM image of 1 NPs isolated from water.
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matrix ¼ 200  200, measured slice thickness ¼ 3 mm, ETL ¼ 5, TE ¼ 10 ms,
TR ¼ 725 ms, FA ¼ 90). The acquired imaging data were transferred to a computer
runningMatlab and analysed using an in-houseMatlab tool to receive the relaxation
times T1 and T2 for each NP concentration (in terms of [Fe] or [Fe]þ [Mn]). Excel was
used to plot the relaxation rates against concentration and the relaxivity (i.e.
gradient of linear ﬁt) determined from a least squares ﬁt.
2.9. In vivo PET/MR imaging
A 6e7 weeks old female C57 black mouse with a weight of 20e21 g was used.
Animal experiments were carried out at the Nanobiotechnology & In Vivo Imaging
Center, Semmelweis University in Hungary, with permission from the local insti-
tutional animal ethics committee and in compliance with the relevant European
Union and Hungarian regulations. PET/MRI images were recorded on a nanoScan (r)
integrated PET/MRI system (Mediso, Budapest, Hungary), in which the MR is a
preclinical 1T MRI scanner (M2, Aspect Imaging) with horizontal bore magnet, so-
lenoid coil (diameter of 35 mm) and 450 mT/m gradients. Mice were anaesthetised
with isoﬂurane and placed in prone position on the MRI bed. After the pre-contrast
MR scan, 85 ml 18F-labelled (as described above, Section 2.3) NPs 3 solution in saline
containing 0.95 MBq-ﬂuoride radioactivity and ca. 60 mg Fe was injected via the tail
vein. PET scanning was started immediately after injection and continued for
120 min. Acquisition took place in 1e5 coincidence mode with 5 ns coincidence
window, 400e600 keV energy window, 94.7 mm scan range. A 3D expectation
maximisation (3D EM) PET reconstruction algorithm (Mediso Tera-Tomo TM) was
applied to produce PET images including corrections for attenuation and scatter,
dead time, decay and randoms. After 8 iterations the reconstruction stopped
resulting in images with 0.1 mm voxel size and time frames of 8  15 min. MR
scanning was performed immediately after PET. The images of the two modalities
were fused automatically.2.10. In vivo PET/CT imaging
Two normal young C57BL/6 mice were used, at KCL in accordance with UK
Research Councils’ and Medical Research Charities’ guidelines, under a UK Home
Ofﬁce licence. Mice were anaesthetised with isoﬂurane (Section 2.9) and 100 ml
0.5 mg/ml solution of 1 labelled with 6.98 MBq 64Cu (as described in Section.) in
saline, containing 0.2 mg/ml PEG (5 K), was injected via tail vein. In the case of PET/
CT imaging with 18F radiolabelled MnFe2O4@Al(OH)3-BP-PEG NPs (Sections 2.3 and
2.2.5), 105 mg NPs in 100 ml saline solution containing 4.48 MBq [18F]-ﬂuoride
radioactivity was injected. In the case of the control PET/CT imagingwith “free 64Cu”,
50 ml 64CuCl2 solution bufferedwith sodium acetate (containing 5MBq radioactivity)
was injected intravenously via the tail vein. PET scanning was commenced imme-
diately after injection of NPs using a NanoPET/CT scanner from Mediso, with PET
acquisition time 120 min with a coincidence mode 1e5 and energy window 400e
600 keV. CT scans were performed immediately after PET. Adjoint Monte Carlo was
used for reconstruction, while the detector model and the number of iterations/
subsets were LOR ﬁlter and 5/6, respectively.
3. Results and discussion
Typically, MnFe2O4@Al(OH)3 NPs (1) were obtained by adding a
diethyl ether (Et2O) solution of AlCl3 to a Et2O solution of MnFe2O4
NPs, at the selected mole ratios, whilst stirring. After 10 min, the
black mixture was treated with water (500 ml) to induce controlled
hydrolysis and stirred for a further hour. The particles were
precipitated out by the addition of 10 ml acetone, and then isolated
by centrifugal ﬁltration, washed with ethanol and re-dispersed in
water. Fe3O4@Al(OH)3 samples with different Fe:Al ratios (2e4)
Fig. 2. (a) No carrier added [18F]-ﬂuoride radiolabelling of NPs 1 in water; (b) the amount of radioactivity remaining on 18F-ﬂuoride labelled 1 NPs after washing with water 1, 2 and
3 times respectively; and (c) the amount of radioactivity remaining on NPs after incubation in human serum for different times (0e360 min). In the case of 0 min, the radiolabelled
NPs were dissolved in serum in a 1 ml NanoSep with membrane, and then immediately isolated from serum by centrifugation.
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added prior to the addition of acetone and AlCl3 was hydrolysed
rapidly when the NPs were dispersed in water, rather than by
addition of a small amount of water in Et2O. Two weak peaks
around 21 in the XRD pattern appeared after coating and were
associated with the nordstrandite phase of Al(OH)3 (Fig. 1a) [22].
The infrared spectrum of all Al(OH)3 coated samples showed the
disappearance of adsorption peaks of CeH at 2845 cm1 and
2950 cm1 after coating with Al(OH)3, conﬁrming that oleylamine
had been removed, and the appearance of three absorption peaks at
842 cm1 and 1645 cm1 and a broad band from 3000 to
3500 cm1, corresponding respectively to the AleO stretching [23],
the deformation vibration of water, and OeH stretching mode
(Fig. S1). Nanoparticulate MnFe2O4 is soluble in hexane but insol-
uble inwater due to the organic layer (oleylamine and oleic acid) on
the surface. Once coated with Al(OH)3, the NPs become soluble in
water but insoluble in hexane (Fig. 1b). All these features suggest a
coating of Al(OH)3 replacing the oleylamine on the iron oxide NPs.
Transmission electron microscopy (TEM), however, revealed no
obvious difference size or morphology before and after coating
with Al(OH)3 (Fig. 1ced, Fig. S2). This could be attributed to the
poorly crystalline and low-density nature of shell, indicated by the
weak and broad diffraction peak on XRD pattern in Fig. 1a and
Fig. S3.
X-Ray photoelectron spectroscopy (XPS) spectrum and induc-
tively coupled plasma mass spectrometry (ICP-MS) both indicated
that the content of Al in the shell increased with increasing ratios ofAlCl3 to magnetic NPs (Table S1, Figs. S4 and 5). NPs with insufﬁ-
cient Al(OH)3, for example 2 tended to aggregate strongly in water,
as indicated by TEM images (Fig. S2) and exhibited large hydro-
dynamic size (hydrodynamic diameter, Dh) up to 400 nm as
measured by dynamic light scattering (DLS) experiments
(Table S2). This suggested the important role of Al(OH)3 in stabil-
ising iron oxide NPs inwater by converting the hydrophobic surface
of oleylamine-coated Fe3O4 NPs into a hydrophilic surface, as well
as offering a highly positive surface potential to protect them from
aggregation. DLS experiments conﬁrmed that NPs 3 exhibited a
highly positive zeta potential up to þ70 mV, and a small Dh of
21 nm, reduced from 43.8 nm for Fe3O4 in hexane (as measured by
DLS). These coated NPs were stable in water with no obvious
changes in Dh for over 12 months.
Another beneﬁt of the Al(OH)3 coating is its high afﬁnity to
ﬂuoride ions and bisphosphonate groups [16,17], which allows a
simple and easy approach for radiolabelling with [18F]-ﬂuoride or
metallic radionuclides conjugated with bisphosphonate. Indeed, a
nearly 100% labelling efﬁciency (LE) was achieved by simply mixing
a solution of NPs 1with radioactive 64Cu(DTCBP)2 solution (Fig. 4a)
[15] at room temperature for no more than 5 min, and no radio-
activity was observed in the supernatant. Moreover, NPs 1 exhibi-
ted a high labelling efﬁciency (LE) with no-carrier-added [18F]-
ﬂuoride of up to 97% using as little as 10 mg NPs (Fig. 2). The
adsorption of ﬂuoride ions by Al(OH)3-coated NPs was further
conﬁrmed using a ﬂuoride selective electrode, with cold NaF
instead of tracer level radioactive 18F (Fig. S6). The binding capacity
Fig. 3. Left: T2 and T2* weighted MR images of aqueous solutions of the NPs 3 (upper series) or the NPs 3 after being washed with water using NanoSep (lower series); right: curves
of relaxivity against concentration at 3T (red circles, r2*; black squares, r2; blue triangles, r1). The concentration of Fe was measured by ICP-MS.
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higher than 4e7 mg/g observed for hydroxyapatite [16,25]). The
kinetic stability of 18F binding to NPs (0.34 mg and 0.68 mg) was
investigated in water and in serum. The results demonstrated that
over 99.8% 18F remained on the NPs even after washing with water
three times (Fig. 2b). However, the stability appeared to become
diminished with a smaller sample of NPs (0.07 mg). This may be
simply a result of mechanical losses due tomanipulation of the very
small sample. Studies on the dynamic stability in human serum
indicated that there was a slow release of 18F from radiolabelled
NPs 1 over a period of 4 h, with ca. 40% 18F remaining on NPs afterFig. 4. Structure of 64Cu(DTCBP)2, the bisphosphonate derivative used to bind 64Cu to NPs (a)
mouse after intravenous injection with 64Cu radiolabelled 1, showing dynamic biodistribut4 h incubation and no obvious further release of 18F-ﬂuoride af-
terwards. The release of 18F into serum could be a combination of
the dissociation of loosely bonded 18F from the surface, the sub-
stitution by other anions in serum, interaction with proteins in
serum via hydrogen bonding or ion pairing, and the dissolution of a
labile fraction of the Al(OH)3 layer.
Interestingly, initial results suggested that Fe3O4@Al(OH)3
samples (2e4), prepared by a fast, uncontrolled hydrolysis process,
are much less efﬁcient in radiolabelling with 18F than their ana-
logues 1 prepared by controlled hydrolysis (Fig. S7). Moreover, NPs
coated with a thicker Al(OH)3 layer, for example NPs 3 and 4,; and in vivo PET/CT images (maximum intensity projection) of a normal young C57BL/6
ion of NPs, 0e15 min (b) and 105e120 min (c).
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2 have a thinner shell and correspondingly lower colloidal stability.
These phenomena lead to the hypothesis that a quick hydrolysis
with large amount of water resulted in an unstable Al(OH)3 layer on
the NPs (2e4) whereas a slow hydrolysis with a small amount of
water in Et2O led to a stable layer (1). An external unstable Al(OH)3
layer would be washed into the supernatant during the separation
process, resulting in a low value of LE. By monitoring the Al con-
centration in the supernatant after washing and comparing to the
initial solution by ICP-MS, we found that almost half of the
aluminium was washed out at the ﬁrst wash for samples 3 and 4
which were synthesised by the quick hydrolysis process. The
aluminium remaining on the NPs after washing was stable since no
Al was detected in the supernatant after further washing (Table S3).
Correspondingly, these NPs 2e4 displayed a high afﬁnity to [18F]-
ﬂuoride after washing, of up to 94.9%. Only trace amounts of Al
were detected in the supernatant of 1, which suggested a stable
layer of Al(OH)3 consistent with the excellent radiolabelling results
above.
As expected, these Al(OH)3-coated NPs displayed essentially the
magnetic properties of the cores and were active as contrast agents
in MR imaging, showing a darkening contrast on the T2 or T2*
weighted MR images of solutions of NPs as a result of shortening
transverse relaxation time of water molecules (Fig. 3). The trans-
verse relaxivity property (r2) of the NPs strongly depends on the
shell thickness, weakening dramatically as the Al(OH)3 shell
thickness increases (3 and 4), consistent with previous reports that
relaxivity is proportional to the volume fraction of magnetic ma-
terials [26]. Fe3O4@Al(OH)3 samples 3 and 4 displayed higher
relaxivities (r1 and r2) after washing off the unstable layer; for
example, r2 was improved from 81.6 to 121.9 mM1 s1 for NPs 3,
and from 60.5 to 116.6 mM1 s1 for NPs 4 at 3T magnetic ﬁeld
(Fig. 3, Table S2). For the samples with a stable layer (1), no obvious
improvement was observed on the relaxivity properties after
washing.
In vivo PET/CT and PET/MR imaging results showed that both 1
and 3 labelled with [18F]-ﬂuoride exhibited a quick uptake, seen
by PET imaging, in the spleen and liver after intravenous injection
via tail vein, despite their small hydrodynamic size of 21 nm in
saline solution. Accumulation of NPs in the spleen and liver was
evident also by MR, in a signiﬁcant darkening contrast in the
corresponding areas on MR images in Fig. S8. The combined im-
ages show that the magnetic cores and the radioactivity co-
localise in the early period after injection but separate with
time. Due to the unstable aluminium hydroxide shell, [18F]-ﬂuo-
ride radioactivity was gradually released from NPs 3 in vivo,
resulting in a signiﬁcant bone uptake increasing with time.
Consistent with in vitro studies presented above, 1 NPs showed a
better in vivo stability and slower, but still signiﬁcant, release of
[18F]-ﬂuoride radioactivity (Fig. S9). By contrast, intravenously
injected free [18F]-ﬂuoride, without NPs, is immediately accu-
mulated in bone and not in liver and spleen. PET/CT imaging a
normal mouse with 1-64Cu(DTCBP)2 showed a similar bio-
distribution to that of 18F radiolabeled NPs (Fig. 4). All intrave-
nously administered NPs were taken up by the spleen and liver
within 2 h post-injection, and showed no sign of efﬂux of radio-
label from these organs, in contrast to the 18F-labelled particles. By
comparison, PET/CT using ionic 64Cu (64CuCl2, Fig. S10) showed
uptake dominated by liver and kidneys but not spleen. This con-
ﬁrms that 64Cu radioactivity attached to NPs via bisphosphonate
groups co-localises with the magnetic cores and is not rapidly
detached from the NPs. The quick clearance of 1 NPs by the liver
and spleen was not unexpected, as the in vivo behaviour is
determined not only by their hydrodynamic size but also by sur-
face properties (surface chemistry and potential) [27,28].Generally, intravenously administered NPs over 100 nm are
readily cleared by the reticuloendothelial system (RES) through
opsonisation, whilst small particles (10e100 nm) tend to stay in
the blood pool longer [27]. Thus, although their hydrodynamic
size as measured in saline or in water was sufﬁciently small, to
achieve stealth features, the Al(OH)3-coated NPs needed further
surface modiﬁcation to neutralise the surface potential. We found
that in this case, polymers with anionic functional groups bound
to the NPs via bisphosphonate groups, such as bisphosphonate
polyethyleneglycol (BP-PEG), could be used to modulate the sur-
face potential of particles (Fig. S11), and protect them from
opsonisation and aggregation in serum.
4. Conclusions
In summary, we have presented a simple approach to convert
hydrophobic iron oxide-based magnetic NPs into hydrophilic par-
ticles stabilised by an Al(OH)3 shell. The features of this system,
including high efﬁciency on 18F or 64Cu labelling, excellent colloidal
stability, small hydrodynamic size, good transverse relaxivity and
controllable surface potential, suggest that materials based on
Fe3O4@Al(OH)3 have potential applications as bimodal contrast
agents in PET/MRI imaging. A slow release of 18F from NPs was
observed in vivo, whereas PET imaging with 64Cu radiolabelled NPs
showed no loss of radioactivity from the initially targeted organs
(liver, spleen). The ability to derivatise the surface with radiolabels
and bisphosphonate groups suggests applications in molecular
imaging. Barriers to in vivo use due to toxicity should be low,
because of the established use of Al(OH)3 as adjuvants in vaccines.
The high afﬁnity to bisphosphonate groups for Al(OH)3 allows us to
conjugate these NPs with a range of imaging and therapeutic ra-
dionuclides which may be used in conjunction with magnetic im-
aging and therapy.
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